Flicker C, Ferris S H, Kalkstein D, Serby M
Department of Psychiatry, New York University Medical Center, NY 10016.
Am J Psychiatry. 1994 Jan;151(1):126-9. doi: 10.1176/ajp.151.1.126.
In a double-blind trial, 12 patients with probable Alzheimer's disease were treated for 6 weeks with placebo and 6 weeks with monosialoganglioside (GM1) (100 mg/day i.m.), which potentiates the actions of nerve growth factor. GM1 failed to produce significant improvement in patients' cognitive test performance, suggesting that this is not a viable approach to the treatment of cognitive deterioration in Alzheimer's disease.
在一项双盲试验中，12名疑似阿尔茨海默病患者接受了为期6周的安慰剂治疗，以及为期6周的单唾液酸神经节苷脂（GM1）（每日100毫克，肌肉注射）治疗，GM1可增强神经生长因子的作用。GM1未能使患者的认知测试表现产生显著改善，这表明这不是治疗阿尔茨海默病认知衰退的可行方法。
